RESEARCH MATERIALS • BATCH DOCUMENTATION • SECURE PACKAGING
PLPEPTRIONLABS
← Back to catalogue
Retatrutide research presentation
AVAILABLERESEARCH MATERIAL

Retatrutide UK – 50mg Research Peptide

£199.99£129.99SaleTaxes included.

Retatrutide 50mg research peptide supplied in the UK in a single pen-style research presentation. Researchers looking to buy Retatrutide UK research material can review the exact product format, current batch status and available documentation before ordering. Supplied strictly for laboratory, analytical and scientific research use only.

Not supplied for human consumption, personal use, veterinary use, diagnosis, treatment or administration.
Price£199.99 £129.99

Taxes included.

Secure Pay by Bank checkout powered by Fena.

UK dispatchSame-day dispatch before 2pm, Monday–Friday
ShippingSecurely packaged. View shipping information →
Batch documentationReference batch documentation is available for a separate Retatrutide 30 mg sample: lot TP260620, sample E75D-VDUL, published 29 July 2026. The report records 31.08 mg measured quantity and 99.984% total blend purity. This reference report does not certify the currently listed 50 mg presentation or any other batch. Open COA ↗
Research use onlyNot for human or veterinary use. Read policy →

Product facts

  • 50mg total content
  • Single pen-style research presentation
  • Current batch status shown below
  • UK stock and tracked dispatch

Research-use notice

  • Not supplied for human consumption, personal use, veterinary use, diagnosis, treatment or administration.

Documentation

  • Where applicable, supporting documentation is available for product identification and quality-control review. It is not medical or clinical guidance.

RESEARCH PROFILE

About Retatrutide

Retatrutide peptides are investigated in receptor-pharmacology research because retatrutide (LY3437943) is designed to activate GIP, GLP-1 and glucagon receptors. Current research includes metabolic signalling, energy-expenditure models and comparison of single-, dual- and triple-receptor agonism. The compound remains investigational.

Research areas

Research involving retatrutide includes incretin-receptor pharmacology across its three target receptors, metabolic signalling, energy-expenditure and appetite-signalling models, and comparative investigation of single-, dual- and triple-receptor agonism.

This listing is supplied as research material. Product documentation should be consulted for batch-specific handling and storage information.

This Retatrutide peptide UK listing is for in vitro laboratory research. Available certificates of analysis must be matched to the specific sample and batch; a report for another presentation does not certify the currently listed 50mg product.

For laboratory research use only. This product is not a drug, food or supplement and is not intended for human or veterinary use, diagnosis, treatment or administration.

PRODUCT RECORD / 01

A precise product record, not a generic product claim.

This record separates the listed presentation, documentation state and research context so that label information is not mistaken for independent analytical evidence.

Reference COA available · 30 mg sample

LABEL SPECIFICATION / 02

The presentation, without assumptions.

These fields describe the current listing. They are not independently verified results for identity, purity, content, sterility or quality.

CompoundRetatrutideThe compound named in the current Peptrion Labs product listing.
Labelled amount50 mgLabel information only. A matching quantitative assay is required to verify content.
Pack contentsSingle research presentationThe current presentation supplied with this listing.
Listed stateListed product presentationPhysical/listing description only; not independent evidence of identity or quality.
Research classificationInvestigational triple receptor agonistClassification describes the research context and is not a claim of regulatory approval.
Development identifierLY3437943Identifier associated with the compound in sponsor research.

EVIDENCE BOUNDARIES / 03

What a laboratory report can — and cannot — show.

A matching report may support

  • Identity when an appropriate identification method is reported for the matching sample and batch.
  • Purity by the specific chromatographic method and calculation stated in the report.
  • Content or mass only where that measurement is explicitly included.

A report does not automatically establish

  • Clinical effectiveness, therapeutic benefit or fitness for personal use.
  • Sterility, endotoxin or contaminant status unless those tests are separately reported.
  • Regulatory approval or authorisation as a medicine.

BATCH DOCUMENTATION / 04

Certificate & batch record

Reference document only

The available report covers a separate 30 mg Retatrutide sample. Match the report details before relying on it. It does not certify the currently listed 50 mg presentation or any other batch.

Retatrutide 30 mg sample · 29 July 2026

Lot codeTP260620
Sample codeE75D-VDUL
Report presentation30 mg sample
Reported total blend purity99.984%

The uploaded certificate identifies Retatrutide, a 30.0 mg sample, lot TP260620 and sample E75D-VDUL. It reports 31.08 mg total quantity and 99.984% total blend purity. These results apply to that identified sample and lot only.

Open original PDF ↗ Documentation guide →

DOCUMENTATION PROCESS / 05

What a publishable batch record requires.

01Match the presentationCompound, labelled amount, container format and sample description should correspond.
02Match the batchThe identifier on the product record, packaging and report should be the same.
03Record method & scopeLaboratory, report number, date, analytical method, result and stated limitations should be preserved.
04Publish the originalThe complete original report is preferable to a cropped badge or rewritten percentage.

SOURCE REGISTER / 06

Verify status and context at the source.

Regulatory status, sponsor information and batch analysis answer different questions. Sources are labelled so they are not mistaken for laboratory evidence.

Molecule & development statusEli Lilly and Company · primary sponsor source ↗ UK regulatory recordMHRA · Retatrutide appears in the UK paediatric investigation-plan register ↗

QUESTIONS / 07

Questions a credible product record should answer.

Is Retatrutide an approved medicine?

No approval claim is made on this page. Lilly describes retatrutide as investigational and in Phase 3 development. Regulatory status should be checked directly with the relevant regulator and sponsor source.

When will a certificate be shown as linked?

Only when Peptrion Labs has a report whose product, labelled amount, presentation and batch identifiers can be matched to the product record and the original report can be published.

Does an HPLC purity percentage prove peptide content?

Not necessarily. Chromatographic area purity and quantitative content are different measurements. The analytical method and scope stated in the original report must be reviewed.

What does the available 30 mg reference report cover?

It covers the identified 30 mg Retatrutide sample, lot TP260620 and sample code E75D-VDUL. It does not certify the currently listed 50 mg presentation or another batch.

Does this page provide dosing or administration guidance?

No. Peptrion Labs product records provide research-product information only and do not provide dosing, injection, administration, treatment or personal-use guidance.

RESEARCH LIBRARY / 08

Method notes and research context.

Research libraryResearch material overviewsBackground information with clear evidence boundaries. DocumentationUnderstanding COAs and analytical reportsHow to read methods, identifiers and reported results. PolicyResearch-use informationScope, responsibilities and website information boundaries.